DSL(SH:603233) Xin Lang Cai Jing·2025-10-20 06:00Group 1 - The core viewpoint of the news is that Dazhenglin's stock has experienced a significant increase, with a 5.2% rise on October 20, reaching a price of 18.41 yuan per share, and a total market capitalization of 20.966 billion yuan [1] - Dazhenglin Pharmaceutical Group Co., Ltd. is based in Guangzhou, Guangdong Province, and was established on February 12, 1999. It was listed on July 31, 2017. The company's main business includes retail of Chinese and Western medicines, health products, and medical devices [1] - The revenue composition of Dazhenglin's main business is as follows: 76.88% from Chinese and Western medicines, 10.49% from non-pharmaceutical products, 9.75% from Chinese medicinal materials, and 2.88% from other supplementary products [1] Group 2 - From the perspective of fund holdings, one fund under Zhongyou Fund has a significant position in Dazhenglin. The Zhongyou CSI 500 Index Enhanced A Fund (590007) held 56,000 shares in the second quarter, accounting for 1.46% of the fund's net value, making it the fifth-largest holding [2] - The fund has generated a floating profit of approximately 51,000 yuan today, with a total floating profit of 49,300 yuan during the four-day increase [2] - The Zhongyou CSI 500 Index Enhanced A Fund was established on November 22, 2011, with a latest scale of 43.1504 million yuan. Year-to-date returns are 20.24%, ranking 2269 out of 4219 in its category, while the one-year return is 26.96%, ranking 1976 out of 3866 [2]